Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Not Seeking To Undercut Incivek, Victrelis On Olysio’s Pricing

Executive Summary

While Olysio will be priced higher than Incivek for the course of therapy, J&J has a broader strategy for use of the second-generation protease inhibitor. Market analysts are skeptical about the drug’s prospects even though it has some clear edges over the first-generation protease inhibitors for hepatitis C.

Advertisement

Related Content

Medicare Will Be Leading Payer For Hepatitis C By 2017 – Milliman Report
FDA Approval Of Gilead’s Sofosbuvir Shows Flexibility On HCV Combos
FDA Approval Of Gilead’s Sofosbuvir Shows Flexibility On HCV Combos
Telaprevir Labeling Advantages Should Offset Higher Price In Hepatitis C Battle
Vertex Prices Telaprevir At $49,200 For Course Of Therapy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055779

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel